 Designer Drugs
"Designer Drugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines.
| Descriptor ID |
D015198
|
| MeSH Number(s) |
D26.200
|
| Concept/Terms |
Designer Drugs- Designer Drugs
- Drugs, Designer
- Customized Drugs
- Drugs, Customized
|
Below are MeSH descriptors whose meaning is more general than "Designer Drugs".
Below are MeSH descriptors whose meaning is more specific than "Designer Drugs".
This graph shows the total number of publications written about "Designer Drugs" by people in this website by year, and whether "Designer Drugs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 | | 2016 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Designer Drugs" by people in Profiles.
-
Krueger JN, Wilmot JH, Teratani-Ota Y, Puhger KR, Nemes SE, Crestani AP, Lafreniere MM, Wiltgen BJ. Amnesia for context fear is caused by widespread disruption of hippocampal activity. Neurobiol Learn Mem. 2020 11; 175:107295.
-
Hamlett ED, Ledreux A, Gilmore A, Vazey EM, Aston-Jones G, Boger HA, Paredes D, Granholm AE. Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome. Neurobiol Dis. 2020 02; 134:104616.
-
Wang GS, Hoyte C. Novel Drugs of Abuse. Pediatr Rev. 2019 Feb; 40(2):71-78.
-
Grace PM, Wang X, Strand KA, Baratta MV, Zhang Y, Galer EL, Yin H, Maier SF, Watkins LR. DREADDed microglia in pain: Implications for spinal inflammatory signaling in male rats. Exp Neurol. 2018 06; 304:125-131.
-
Armenian P, Darracq M, Gevorkyan J, Clark S, Kaye B, Brandehoff NP. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. Neuropharmacology. 2018 05 15; 134(Pt A):82-91.
-
Giannotti G, Canazza I, Caffino L, Bilel S, Ossato A, Fumagalli F, Marti M. The Cathinones MDPV and a-PVP Elicit Different Behavioral and Molecular Effects Following Acute Exposure. Neurotox Res. 2017 Nov; 32(4):594-602.
-
Carlier J, Diao X, Sempio C, Huestis MA. Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS J. 2017 03; 19(2):568-577.
-
Riederer AM, Campleman SL, Carlson RG, Boyer EW, Manini AF, Wax PM, Brent JA. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Jul 15; 65(27):692-5.
-
Srisuma S, Bronstein AC, Hoyte CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol (Phila). 2015; 53(7):624-8.
-
Booth RE. 'Krokodil' and other home-produced drugs for injection: a perspective from Ukraine. Int J Drug Policy. 2013 Jul; 24(4):277-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|